<DOC>
	<DOCNO>NCT02801591</DOCNO>
	<brief_summary>Observe clinical efficacy safety Recombinant Human Growth Hormone Injection assist treatment patient poor ovarian response vitro fertilization embryo transfer .</brief_summary>
	<brief_title>Effect Recombinant Human Growth Hormone Injection Clinical Outcome POR Patients Undergoing IVF/ET</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>Female , age 3042 year old . Diagnosis POR ( 2011 ESHRE Bologna Standard ) . At least two previous IVF failure history . Voluntarily sign `` informed consent '' . Severe acute chronic liver kidney disease，Such liver cirrhosis , acute chronic renal failure , hepatitis B virus activity period , etc.；Liver kidney dysfunction . Endocrine metabolic diseases，eg , diabetes、Thyroid function hyperthyroidism , Thyroid dysfunction , cushing 's syndrome , hyperprolactinemia，hyperandrogenism . Related disease affect outcome IVF pregnancy，eg , hydrosalpinx , hysteromyoma≥4cm , adenomyosis , stage III IV endometriosis , untreated endometrial lesion , uterine malformation , genital tuberculosis , malignant tumor reproductive system （include endometrial carcinoma , cervical carcinoma , ovarian cancer , fallopian tube carcinoma） . Allergic E. coli expression product excipients . Subjects participate past three month participate drug clinical researcher . IVF failure history≥3 . The researcher consider suitable enrol group .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>